oppn parties Covid Vaccines Cannot Be Priced As Any Other Vaccine

News Snippets

  • India's sovereign green bonds were oversubscribed four times as the RBI received 266 bids worth Rs 32892cr agaisnt the target of Rs 8000cr
  • Google tweaks its Android and India app store policy to allow manufacturers and users to choose certain things instead of compulsorily using Google apps after the CCI order and fine for unfairly dominating the market
  • Former US secretary of state calls former Indian external affairs minister Sushma Swaraj a "goofback" and a "hinterland political hack". MEA S Jaishankar slams him
  • Jamia screening of BBC documentary on Gujarat riots cancelled after the university was turned into a fortress and later 13 students were detained by the police
  • Supreme Court grants conditional interim bail for eight weeks to Lakhimpur Kheri accused Ashish Mishra. The bail can be further extended based on his conduct. He was asked to stay outside Delhi-NCR and UP and surrender his passport
  • After the JNU administration tried to thwart the students from screening the BBC documentary on the Gujarat riots and PM Modi, now students of Presidency and Jadavpur universities in Kolkata have decided to screen it 5 times next week
  • While a US research frim Hindenburg says its analysis found the Adani group overleveraged and claimed that its bubble will burst very soon and that sent the price of group companies crashing (Adani companies lost a combined Rs 55000cr), Adani group said the report was 'baseless' and 'malicious'
  • This time Enforcement Directorate arrests TMC spokesperson Saket Gokhale under PMLA for money laundering
  • Padma awards announced on Republic Day: Mulayam Singh Yadav, architect Balkrishna Doshi and ORS pioneer Dilip Mahalanobis get Padma Bibhushan posthumously, Padma Bhushan ius awarded to Kumar Mangalam Birla and 8 others and 91 get Padma Shri
  • Stocks fall big time on Wednesday on F&O expiry, finalncial and banks take big hit: Sensex tumbles 773 points to 60205 and Nifty 226 points to 17892 even as the market volatility meter shoots up by 8.51%
  • World Cup hockey: Germany stun England 4-3 to reach semifinals; Netherlands beat Korea 5-1 to enter last four
  • Australian Open: Sania Mirza and Rohan Bopanna reach the finals
  • Suryakumar Yadav is named ICC Cricketer of the Year 2022 and Renuka Singh gets the ICC Emerging Cricketer of the Year 2022 award
  • BCCI gets a whopping Rs 4670cr in the auctions for the 5 teams in WIPL or as it will be known now, WPL. Adani Sportline gets Ahmedabad for Rs 1289cr while Mumbai Indians get Mumbai for 913cr
  • Calcutta HC overturns the hookah bar ban in Kolkata by saying that it is not an illegal trade
India Commentary Wishes A Happy Republic Day To All Its Readers /////// India Commentary Wishes A Happy Basant Panchami And Saraswati Puja To All Its Readers
oppn parties
Covid Vaccines Cannot Be Priced As Any Other Vaccine

By Sunil Garodia
First publised on 2021-06-16 11:38:25

About the Author

Sunil Garodia Editor-in-Chief of indiacommentary.com. Current Affairs analyst and political commentator.

Both Serum Institute and Bharat Biotech, makers of Covishield and Covaxin respectively, have urged the government to raise the price at which it is acquiring the Covid vaccines from them. Their argument is that the average price (reported to be in the range of Rs 200 to Rs 250 per dose excluding taxes) now is not sustainable due to the fact that a lot of costly R&D went into developing the vaccines and they have to upgrade their facilities. They say that at current price, they are just recouping their costs and making a small profit. But, they say, they have to make super profits to recoup R&D costs and for future R&D.

Their arguments are perfectly logical. But that is in the case of any other vaccine. In case of Covid vaccines, these arguments do not hold. For, most other vaccines take years to develop and then several more years to test and market. The Covid vaccines were developed, tested and administered in a record 10 to 11 months. Then, most other vaccines are sold in thousands of doses over a period of several years. Here we are talking about millions of doses in a span of just one year. Also, most other vaccines need extensive marketing which is a costly exercise. Commissions have to be paid at each point in the sales channel. Even doctors have to be 'paid' to prescribe their brand if there are competing vaccines. Companies also have attractive schemes for the trade (like "buy three, get two free" etc) for most other vaccines. Lastly, in all other vaccines, there are expired and unsold products, sometimes to the extent of 5% of sales, which the companies have to take back from the market. The companies are saving all these costs. Further, in the case of Covaxin, the government of India, through ICMR, has contributed funds in R&D.

If the companies say that these costs are not sustainable, the government must sit with them to renegotiate the price. But the pricing of vaccines which are to be procured in millions of doses in a short span of time and for which the government is making advance payment in part cannot be priced in a manner similar to any other vaccine. The companies have to keep this in mind.